As a leader in health and agriculture, something is always happening at Bayer in the U.S. and in the countless communities we serve. Take a look below—and check back often—to explore some of our most exciting news and stories as they emerge.
These contacts are for media inquiries only.
All other inquiries can be directed to:
Bayer Corporation
100 Bayer Boulevard
Whippany, NJ 07981
Phone: 862-404-3000
Click here for general inquiries.
Click here to report an adverse event.
Click here if you are a US healthcare professional seeking medical information.
General U.S. Media Inquiries
USmediainquiries@bayer.com
Click here for Global Media Inquiries
Nicole Hayes
Director, U.S. Communications
201-421-5268
Nicole.Hayes@bayer.com
Brian Leake
Director, External Communications
314-370.3285
brian.leake@bayer.com
Kyel Richard
Deputy Director, External Communications
573-356-0241
kyel.richard@bayer.com
Sue Ann Pentecost
U.S. Communications
910-221-6446
Sueann.pentecost@bayer.com
Bayer Statement on mRNA Lawsuits
Bayer did not manufacture and has never manufactured the COVID vaccine. This lawsuit alleges the defendants infringed on patented innovations owned by Bayer which increase mRNA stability and which Bayer initially used [for agricultural purposes]. The defendants’ unlicensed use of Bayer’s intellectual property enabled them to address mRNA instability, solving one of the biggest challenges they faced during vaccine development.
Statement on RoundUp Active Ingredient Safety
American Agriculture at Risk- An Open Letter on Glyphosate
Bayer statement on Monsanto/glyphosate trial
Bayer statement on Xarelto March 25, 2019
Kogenate FS Recall Healthcare Provider Notification
Kogenate FS Recall Bayer Response to NHF/HFA
Statement on Delaware Supreme Court’s Decision (Nov. 2023)
“Bayer is pleased with the Delaware Supreme Court’s decision to affirm the Chancery Court’s dismissal with prejudice of Merck’s meritless case against the company. The Supreme Court’s affirmance is based on the same reasons given by the Chancery Court, which found that Merck was solely liable and responsible for all product-liability claims relating to the time before the closing of the Purchase Agreement between the two companies under its terms.”
